Immunoefficacy of Recombinant Vaccine
MDS offers custom monoclonal and polyclonal antibody development for recombinant vaccine. This approach involves the direct immunization of the host animal with plasmid DNA encoding the client's protein of interest. The immunized host then produces the encoded protein and raises antibodies. Genetic immunization is perfectly suited to producing antibodies when a protein is difficult to express, purify or when a gene has been obtained, but the protein itself is unknown.
- Large-scale synthesis and purification of proteins are no longer necessary.
- Antibodies are directed only against the encoded protein.
- Unwanted antibodies to contaminants found in purified protein preparations are eliminated.
- Plasmid DNA also acts as an adjuvant to stimulate immune responses.
- These antibodies can be used in many applications, including, but not limited to, purifying proteins from cells or tissues, identifying proteins in prognostic and diagnostic assays, etc.
- No additional charge when used with either monoclonal or polyclonal antibody development programs.
- Choice Of Expression Vector
- Confirmation Of Protein Production
- Preparation Of DNA For Immunization
- Evaluation Of Immunized Animals
- Suitability of the Antigen